Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Wave Life Sciences soars on positive DMD trial results
Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Wave Life Sciences’ WVE-N531 Shows Best-in-Class Potential in DMD Treatment, Justifying a Buy Rating
H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences (NASDAQ: WVE), whose shares rose 9% the day after the central bank reduced rates by 50 basis points.
Wave Life Sciences gains on data for Duchenne therapy
Wave Life Sciences (WVE) stock rises on positive interim data from a Phase 2 trial for for WVE-N531, a therapy for Duchenne muscular dystrophy (DMD). Read more here.
Wave Life Sciences Shares Climb Premarket on Duchenne Study Data
Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy.
Buy Rating on Wave Life Sciences: Undervalued DMD Program and Promising Data Offer Investment Upside
Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and keeping the price target
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531. Explore more details here.
pharmaphorum
1d
Surfing on new Duchenne data, Wave charges $175m offering
Shares in Wave rose 53% after the trial data was announced, taking its market cap above the $1 billion threshold. The company ...
Zacks.com on MSN
1d
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
Shares of Wave Life Sciences WVE surged 53.4% on Tuesday after the company announced positive interim data from a mid-stage ...
2d
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular ...
FierceBiotech
2d
Wave surfs DMD success to regulators' doors, sending stock up
Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...
Zacks.com on MSN
7h
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight ...
BioWorld
2d
Wave Life soars on WVE-N531 phase II Duchenne data
Interim phase II data of Wave Life Sciences Ltd.’s oligonucleotide,
WVE-N531
, revealed “impressive” dystrophin expression, ...
1d
Wave Life And Capricor Surge Forward With Hope - Are These Stocks In Your Portfolio?
Duchenne muscular dystrophy, or DMD, is a severe genetic disorder, typically affecting males, and is characterized by progressive ...
Yahoo Finance
1d
Wave’s stock swells as it eyes approval following Phase II DMD victory
Patients in the Phase II FORWARD-53 trial (NCT04906460) benefitted from substantial dystrophin expression and the
WVE-N531
, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Wave Life Sciences
Duchenne muscular dystrophy
Feedback